Mirum Pharmaceuticals (MIRM) Gross Margin (2021 - 2026)

Mirum Pharmaceuticals' Gross Margin history runs 6 years deep, the most recent figure standing at 81.98% for Q1 2026.

• On a quarterly basis, Gross Margin rose 261.0% year-over-year to 81.98% in Q1 2026; TTM through Mar 2026 was 81.39%, a 428.0% increase from a year earlier, with the FY2025 full-year figure at 80.77%, up 501.0% from the prior year.
• Gross Margin advanced to 81.98% in Q1 2026 per MIRM's latest filing, from 81.02% in the prior quarter.
• Across five years, Gross Margin topped out at 85.56% in Q2 2022 and bottomed at 64.03% in Q4 2023.
• The 5-year median for Gross Margin is 81.02% (2025), against an average of 79.46%.
• Across the five-year window, Gross Margin soared 4454 bps in 2022 and slumped 1987 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 83.9% in 2022, then dropped by 24 bps to 64.03% in 2023, then gained by 20 bps to 77.09% in 2024, then increased by 5 bps to 81.02% in 2025, then climbed by 1 bps to 81.98% in 2026.
• Per Business Quant, the three latest MIRM Gross Margin figures stand at 81.98% (Q1 2026), 81.02% (Q4 2025), and 80.8% (Q3 2025).